100
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Serum Hepcidin-25 and All-Cause Mortality in Patients Undergoing Maintenance Hemodialysis

ORCID Icon, ORCID Icon, &
Pages 3153-3162 | Published online: 05 Jul 2021

References

  • STAFF N-KGD. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279–335.
  • Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010;116(23):4754–4761. doi:10.1182/blood-2010-05-286260
  • Agarwal AK, Yee J. Hepcidin. Adv Chronic Kidney D. 2019;26(4):298–305. doi:10.1053/j.ackd.2019.04.005
  • Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Tar. 2019;23(5):407–421. doi:10.1080/14728222.2019.1599358
  • Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New Engl J Med. 2019;381(11):1001–1010. doi:10.1056/NEJMoa1813599
  • Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New Engl J Med. 2019;381(11):1011–1022. doi:10.1056/NEJMoa1901713
  • Ueda N, Takasawa K. Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients. 2018;10(9):1173. doi:10.3390/nu10091173
  • Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292–4297. doi:10.1182/blood-2008-02-139915
  • Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation?: differential diagnosis and mechanisms of anemia of inflammation. Wien Med Wochenschr. 2016;166(13–14):411–423. doi:10.1007/s10354-016-0505-7
  • Ueda N, Takasawa K. Role of Hepcidin-25 in Chronic Kidney Disease: anemia and Beyond. Curr Med Chem. 2017;24(14):1417–1452. doi:10.2174/0929867324666170316120538
  • Alaaddin K, Ozlem Y, Bulent E, et al. Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients? Hemodial Int. 2016;20:191–197. doi:10.1111/hdi.12355
  • Xu Y, Wang Y, Hu H, Li J, Tian T. Relationship between serum hepcidin levels and cardiovascular disease in patients with maintenance hemodialysis. Physiol Int. 2020;107(4):491–500. doi:10.1556/2060.2020.00040
  • Tessitore N, Girelli D, Campostrini N, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2010;25(12):3996–4002. doi:10.1093/ndt/gfq321
  • Gaillard CA, Bock AH, Carrera F, et al. Hepcidin response to iron therapy in patients with non-dialysis dependent CKD: an analysis of the FIND-CKD trial. PLoS One. 2016;11(6):e0157063. doi:10.1371/journal.pone.0157063
  • Petruliene K, Ziginskiene E, Kuzminskis V, Nedzelskiene I, Bumblyte IA. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Medicina (Kaunas). 2017;53(2):90–100. doi:10.1016/j.medici.2017.03.001
  • Daugirdas JT. Kt/V (and especially its modifications) remains a useful measure of hemodialysis dose. Kidney Int. 2015;88(3):466–473. doi:10.1038/ki.2015.204
  • Suttorp MM, Hoekstra T, Rotmans JI, et al. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol. 2013;14:200. doi:10.1186/1471-2369-14-200
  • Busbridge M, Griffiths C, Ashby D, et al. Development of a novel immunoassay for the iron regulatory peptide hepcidin. Br J Biomed Sci. 2009;66(3):150–157. doi:10.1080/09674845.2009.11730263
  • Reshef DN, Reshef YA, Finucane HK, et al. Detecting Novel associations in large datasets. Science. 2011;334(6062):1518–1524. doi:10.1126/science.1205438
  • Slotki I, Cabantchik ZI. The labile side of iron supplementation in CKD. J Am Soc Nephrol. 2015;26(11):2612–2619. doi:10.1681/ASN.2015010052
  • Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. 2017;18(1):345. doi:10.1186/s12882-017-0688-1
  • Wojtaszek E, Glogowski T, Malyszko J. Iron and chronic kidney disease: still a challenge. Front Med (Lausanne). 2020;7:565135. doi:10.3389/fmed.2020.565135
  • Lee SW, Kim YH, Chung W, et al. Serum hepcidin and iron indices affect anemia status differently according to the kidney function of non-dialysis chronic kidney disease patients: korean Cohort Study For Outcome in Patients with Chronic Kidney Disease (KNOW-CKD). Kidney Blood Press Res. 2017;42(6):1183–1192. doi:10.1159/000485865
  • Gaweda AE. Markers of iron status in chronic kidney disease. Hemodial Int. 2017;21(Suppl 1):S21–S27. doi:10.1111/hdi.12556
  • Ogawa C, Tsuchiya K, Tomosugi N, Kanda F, Maeda K, Maeda T. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study. PLoS One. 2017;12(6):e0179608. doi:10.1371/journal.pone.0179608
  • Wei Y, Zhou J, Zhang Z, et al. Application of restricted cube spline in cox regression model. Zhonghua Yufang Yixue Zazhi. 2020;54(10):1169–1173. doi:10.3760/cma.j.cn112150-20200804-01092